基于肺形态的个性化机械通气与低呼气末正压对ARDS患者预后影响的LIVE随机对照研究
LIVE研究为法国20个ICU开展的多中心、单盲、随机对照试验,纳入420例中重度ARDS患者,比较基于肺形态的个性化机械通气与标准低PEEP策略。
要点
- 个性化机械通气未降低中重度ARDS患者90天死亡率。
- 21%患者肺形态分类错误,错误分类与分组存在显著交互作用。
- 通气策略与肺形态不匹配时死亡率显著增加。
核心结论
- 个性化机械通气未降低ARDS患者90天死亡率,可能与21%患者肺形态分类错误有关。
- 通气策略与肺形态不匹配会显著增加死亡率。
研究设计与样本
- 多中心、单盲、分层、平行组随机对照试验,在法国20个大学或非大学ICU开展。
- 纳入年龄>18岁、早期ARDS持续时间<12小时的中重度ARDS患者,1:1随机分配至对照组或个性化组。
- 仅患者对分组设盲,采用最小化算法并按研究中心、肺形态和机械通气持续时间分层。
- 意向性分析共纳入400例患者(个性化组196例,对照组204例),主要结局为90天死亡率。
主要发现
- 400例患者中85例(21%)被研究者错误分类为局灶性或非局灶性ARDS。
关键数值与推荐
- 对照组:潮气量6 mL/kg预测体重,PEEP按低PEEP与吸入氧浓度表选择,鼓励早期俯卧位。
- 个性化组局灶性ARDS:潮气量8 mL/kg,低PEEP,俯卧位。
- 个性化组非局灶性ARDS:潮气量6 mL/kg,肺复张操作,高PEEP。
临床怎么用
- 对中重度ARDS患者实施个性化通气前需准确评估肺形态,避免分类错误导致策略不匹配。
- 通气策略与肺形态不匹配可能显著增加死亡风险,临床应谨慎选择。
局限性
- 21%患者肺形态分类错误可能影响主要结果解释。
- 仅患者对分组设盲,研究者未设盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of personalised mechanical ventilation on clinical outcomes in patients with acute respiratory distress syndrome (ARDS) remains uncertain and needs to be evaluated. We aimed to test whether a mechanical ventilation strategy that was personalised to individual patients' lung morphology would improve the survival of patients with ARDS when compared with standard of care. METHODS: We designed a multicentre, single-blind, stratified, parallel-group, randomised controlled trial enrolling patients with moderate-to-severe ARDS in 20 university or non-university intensive care units in France. Patients older than 18 years with early ARDS for less than 12 h were randomly assigned (1:1) to either the control group or the personalised group using a minimisation algorithm and stratified according to the study site, lung morphology, and duration of mechanical ventilation. Only the patients were masked to allocation. In the control group, patients received a tidal volume of 6 mL/kg per predicted bodyweight and positive end-expiratory pressure (PEEP) was selected according to a low PEEP and fraction of inspired oxygen table, and early prone position was encouraged. In the personalised group, the treatment approach was based on lung morphology; patients with focal ARDS received a tidal volume of 8 mL/kg, low PEEP, and prone position. Patients with non-focal ARDS received a tidal volume of 6 mL/kg, along with recruitment manoeuvres and high PEEP. The primary outcome was 90-day mortality as established by intention-to-treat analysis. This study is registered online with ClinicalTrials.gov, NCT02149589. FINDINGS: From June 12, 2014, to Feb 2, 2017, 420 patients were randomly assigned to treatment. 11 patients were excluded in the personalised group and nine patients were excluded in the control group; 196 patients in the personalised group and 204 in the control group were included in the analysis. In a multivariate analysis, there was no difference in 90-day mortality between the group treated with personalised ventilation and the control group in the intention-to-treat analysis (hazard ratio [HR] 1·01; 95% CI 0·61-1·66; p=0·98). However, misclassification of patients as having focal or non-focal ARDS by the investigators was observed in 85 (21%) of 400 patients. We found a significant interaction between misclassification and randomised group allocation with respect to the primary outcome (p<0·001). In the subgroup analysis, the 90-day mortality of the misclassified patients was higher in the personalised group (26 [65%] of 40 patients) than in the control group (18 [32%] of 57 patients; HR 2·8; 95% CI 1·5-5·1; p=0·012. INTERPRETATION: Personalisation of mechanical ventilation did not decrease mortality in patients with ARDS, possibly because of the misclassification of 21% of patients. A ventilator strategy misaligned with lung morphology substantially increases mortality. Whether improvement in ARDS phenotyping can decrease mortality should be assessed in a future clinical trial. FUNDING: French Ministry of Health (Programme Hospitalier de Recherche Clinique InterRégional 2013).
引用
- Constantin JM, Jabaudon M, Lefrant JY, et al. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. Lancet Respir Med. 2019. PMID: 31399381. doi:10.1016/S2213-2600(19)30138-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。